Vtama (Tapinarof) Patent Expiration, LOE Window & CMS Spending

Vtama (Tapinarof) by Organon: FDA Orange Book core substance LOE 2038-11-13 (last listed 2039-12-18), 0 AB generics, $54.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOrganon
FDA Application & PathwayN215272 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-11-13
Last Listed Patent or Exclusivity Date2039-12-18
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$54.3M
2024 Medicare Part D Spend$26.7M
2024 Medicaid Spend$27.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Organon across sibling Meru public-data platforms.